IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism
about
Interleukin-1 Family Cytokines in Liver DiseasesEmerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancerA Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in CholangiocarcinomaDifferential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33.Gene expression patterns in CD4+ peripheral blood cells in healthy subjects and stage IV melanoma patients.The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment.Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinomaHepatic myeloid-derived suppressor cells in cancer.Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer.Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.Current strategies to generate mature human induced pluripotent stem cells derived cholangiocytes and future applications.IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis.Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis.Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).The case for immune-based approaches in biliary tract carcinoma.Emerging molecular therapeutic targets for cholangiocarcinoma.Emerging concepts in biliary repair and fibrosis.IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment.Dual roles of yes-associated protein (YAP) in colorectal cancer.Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.Characterisation of the immune-related transcriptome in resected biliary tract cancers.Molecular mechanisms driving cholangiocarcinoma invasiveness: an overview.Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer.YAP-associated chromosomal instability and cholangiocarcinoma in mice.Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of β-Catenin.Patients Treated with Preoperative Chemoradiation for Pancreatic Ductal Adenocarcinoma have Impaired Bone Density, a Predictor of Distant Metastasis.Animal models of cholangiocarcinoma.Understanding liver regeneration to bring new insights to the mechanisms driving cholangiocarcinoma.Innate Lymphoid Cells: A Promising New Regulator in Fibrotic Diseases.Ambiguous roles of innate lymphoid cells in chronic development of liver diseases.Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.The Role of IL-33/ST2 Pathway in TumorigenesisIL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE
P2860
Q26778553-7F0983E5-4D3B-4EA2-8E7D-FF1C921496C6Q28086905-A63FE51A-925A-4ED5-8457-FDCF08505B6AQ36778814-7F9B5C08-8897-47D6-B893-6D284791C234Q36922232-87E969F4-1DD6-432F-9934-9652D1775629Q37251140-4BD234D9-E103-4EDF-BC3A-EAF47730F262Q37343710-89D48866-276C-4739-AC07-AFA3B39FB9B0Q37571181-30D23E7A-B1D6-4F0A-BE1C-15D7184C4A55Q37731958-4F250025-37FD-4E62-8F68-37F2E9710A16Q38541582-DBBA2B3F-E4AF-4BCF-9C20-3814B0CF7826Q38698657-9D307041-1681-497D-A1A1-A4675E0DE806Q38722744-356B7902-E5F4-415E-80DB-65FEDB0DE892Q38753216-737730BD-9CC1-42AD-8A22-EC061498A8F3Q38774569-AAABC9F5-BA0F-4AE9-986B-A78088E9609DQ38775054-F7ECB1AC-167F-4279-B09F-437E8FECE51AQ38779591-17BE158B-DDDD-47E9-B7A5-22A6D9821779Q38812588-30AD11C1-277E-4928-B3ED-8B62EA872AF0Q38833922-B4A8E64C-322C-421A-B6F7-D5F1846FCD08Q39227356-553A3226-C802-45E6-B2EC-3CC39E12DC3EQ39319145-9C1D686E-C4E4-4960-BD40-FFBED2F45B03Q40312760-C19F88F7-5002-46C6-ABFB-9AC42D472AB3Q43651454-6ADBE63B-1E01-416F-B5B6-5871E56BCAB4Q45870005-5C90F69C-DE25-450A-9FE4-F558F1EEA2C1Q46243039-ACAF0AFA-CB69-4020-895F-F3E06283E70AQ47603972-105C18E3-71B4-4C1B-B153-AC626465C10CQ48120429-08F2E69E-F354-4AAB-9054-B03A6EB29C9BQ49787756-504BCA70-8828-4852-A577-3963903E13E2Q50130190-E8D09127-1C54-4ABD-BDEA-F8482F92837FQ50493922-D8F7E153-A094-4BFB-A2E4-1429757CF9F0Q52720960-048FE1AB-EBF3-4851-9239-6587D99F2EDBQ52729640-B7B2C30D-4D59-45F7-970D-7DAEAE3DCE71Q53402699-06B68EC3-BB9B-4530-88BC-2F28505EA420Q55208795-3D7EB621-BC45-4BA0-9D00-A221FD813578Q55662464-E243777A-AC59-47DC-91CA-C034D0B7AC1FQ58756972-5DA35BED-1E80-43D1-890A-4DB55AF45F0BQ58770481-BC324EC0-8DF7-46AC-A674-60136ABA35B9
P2860
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
IL-33 facilitates oncogene-ind ...... erleukin-6-sensitive mechanism
@ast
IL-33 facilitates oncogene-ind ...... erleukin-6-sensitive mechanism
@en
type
label
IL-33 facilitates oncogene-ind ...... erleukin-6-sensitive mechanism
@ast
IL-33 facilitates oncogene-ind ...... erleukin-6-sensitive mechanism
@en
prefLabel
IL-33 facilitates oncogene-ind ...... erleukin-6-sensitive mechanism
@ast
IL-33 facilitates oncogene-ind ...... erleukin-6-sensitive mechanism
@en
P2093
P2860
P356
P1433
P1476
IL-33 facilitates oncogene-ind ...... erleukin-6-sensitive mechanism
@en
P2093
Daisaku Yamada
Jaime I Davila
Jorge A Bezerra
Mia D Champion
Mitesh J Borad
Nataliya Razumilava
Steven F Bronk
Sumera Rizvi
P2860
P304
P356
10.1002/HEP.27687
P407
P577
2015-03-20T00:00:00Z